pvx-410 (OncoPep Inc)
90
Structured Review
OncoPep Inc
pvx-410
Pvx 410, supplied by OncoPep Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pvx-410/pvx+410/pmc12022029__41408_2025_1272_MOESM2_ESM-295-15-8
Average 90 stars, based on 1 article reviews
Pvx 410, supplied by OncoPep Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pvx-410/pvx+410/pmc12022029__41408_2025_1272_MOESM2_ESM-295-15-8
Average 90 stars, based on 1 article reviews
pvx-410 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Injection:Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410, Hiltonol®, and Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: The pharmacy at each study center will order investigational drug kit(s) containing a vial of PVX-410, Montanide, and Article Title: Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma Article Snippet: MAY 2024 BLOOD CANCER DISCOVERY | OF1 Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease.. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety.. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment. Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410 will be supplied by Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: Do not disclose or use except as authorized Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: DF/HCC Protocol #: 16-237 Protocol Version Date: June 22, 2020 TITLE: A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma Coordinating Center: Massachusetts General Hospital Cancer Center Program for Coordination and Oversight of Research Protocols (PCORP) Principal Investigator (PI): Noopur Raje, MD POB 216, 55 Fruit Street Massachusetts General Hospital, Boston, MA Phone: 617 726 0711 Fax: 617 724 31116 nraje@mgh.harvard.edu Other Investigators: Paul Richardson, MD Dana-Farber Cancer Institute prichardson@partners.org David Avigan, MD Beth Israel Deaconess Medical Center davigan@bidmc.harvard.edu Cristiana Costa Chase, MD Duke University Medical Center cristiana.costa@duke.edu Ajay Nooka, MD MPH Emory University – Winship Cancer Center anooka@emory.edu Ehsan Malek, MD University Hospital of Cleveland ehsan.malek@uhospitals.org Rubin Niesvizky, MD Weill Cornell Medical College Run9001@med.cornell.edu Study Statistician: Nora Horick Massachusetts General Hospital NHORICK@mgh.harvard.edu NCI-Supplied Agent(s): Not Article Title: Market watch: Upcoming catalysts in Q2 2015. Article Snippet: There is currently only one other drug in clinical development that targets Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410 will be supplied by Sterility:Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410, Hiltonol®, and Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: The pharmacy at each study center will order investigational drug kit(s) containing a vial of PVX-410, Montanide, and Article Title: Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma Article Snippet: MAY 2024 BLOOD CANCER DISCOVERY | OF1 Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease.. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety.. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment. Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410 will be supplied by Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: Do not disclose or use except as authorized Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: DF/HCC Protocol #: 16-237 Protocol Version Date: June 22, 2020 TITLE: A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma Coordinating Center: Massachusetts General Hospital Cancer Center Program for Coordination and Oversight of Research Protocols (PCORP) Principal Investigator (PI): Noopur Raje, MD POB 216, 55 Fruit Street Massachusetts General Hospital, Boston, MA Phone: 617 726 0711 Fax: 617 724 31116 nraje@mgh.harvard.edu Other Investigators: Paul Richardson, MD Dana-Farber Cancer Institute prichardson@partners.org David Avigan, MD Beth Israel Deaconess Medical Center davigan@bidmc.harvard.edu Cristiana Costa Chase, MD Duke University Medical Center cristiana.costa@duke.edu Ajay Nooka, MD MPH Emory University – Winship Cancer Center anooka@emory.edu Ehsan Malek, MD University Hospital of Cleveland ehsan.malek@uhospitals.org Rubin Niesvizky, MD Weill Cornell Medical College Run9001@med.cornell.edu Study Statistician: Nora Horick Massachusetts General Hospital NHORICK@mgh.harvard.edu NCI-Supplied Agent(s): Not Article Title: Market watch: Upcoming catalysts in Q2 2015. Article Snippet: There is currently only one other drug in clinical development that targets Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410 will be supplied by Histone Deacetylase Assay:Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410, Hiltonol®, and Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: The pharmacy at each study center will order investigational drug kit(s) containing a vial of PVX-410, Montanide, and Article Title: Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma Article Snippet: MAY 2024 BLOOD CANCER DISCOVERY | OF1 Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease.. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety.. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment. Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410 will be supplied by Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: Do not disclose or use except as authorized Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: DF/HCC Protocol #: 16-237 Protocol Version Date: June 22, 2020 TITLE: A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma Coordinating Center: Massachusetts General Hospital Cancer Center Program for Coordination and Oversight of Research Protocols (PCORP) Principal Investigator (PI): Noopur Raje, MD POB 216, 55 Fruit Street Massachusetts General Hospital, Boston, MA Phone: 617 726 0711 Fax: 617 724 31116 nraje@mgh.harvard.edu Other Investigators: Paul Richardson, MD Dana-Farber Cancer Institute prichardson@partners.org David Avigan, MD Beth Israel Deaconess Medical Center davigan@bidmc.harvard.edu Cristiana Costa Chase, MD Duke University Medical Center cristiana.costa@duke.edu Ajay Nooka, MD MPH Emory University – Winship Cancer Center anooka@emory.edu Ehsan Malek, MD University Hospital of Cleveland ehsan.malek@uhospitals.org Rubin Niesvizky, MD Weill Cornell Medical College Run9001@med.cornell.edu Study Statistician: Nora Horick Massachusetts General Hospital NHORICK@mgh.harvard.edu NCI-Supplied Agent(s): Not Article Title: Market watch: Upcoming catalysts in Q2 2015. Article Snippet: There is currently only one other drug in clinical development that targets Article Title: Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Article Snippet: PVX-410 will be supplied by |